Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2010

BioMérieux Makes €9M Investment in Biocartis as Part of MDx Assay Deal

  • BioMérieux has taken a €9 million (about $12.5 million) equity investment in Swiss biotech company Biocartis as part of an exclusive agreement to co-develop microbiology assays on the latter’s multiplex DNA/RNA molecular diagnostics platform. The firms hope to start co-distributing new assays during 2012. The deal also gives bioMérieux access to the Biocartis platform for certain oncology and theranostic assays.

    Biocartis acquired the MDx system from Philips in February, and has been finalizing development and validation at its newly established Dutch subsidiary Biocartis BV. The firm claims the platform is designed to integrate all the steps of a multiplexed molecular assay, from sample in to data out, and minimize hands-on time to just 1-2 minutes. The use of disposable sealed test cartridges avoid contamination risk, and the system is suitable for use in both small and large laboratories and in remote settings, Biocartis adds.  

     “Our team is developing new diagnostics solutions to bridge the gap between the increasing availability of multiple, clinically validated biomarkers and their actual use and deployment in daily clinical practice,” comments Rudi Pauwels, Ph.D., Biocartis founder and CEO. “This collaborative agreement is a fundamental step in Biocartis’ strategy for the introduction of our molecular diagnostics platform.”

    Having acquired the Philips platform in February, Biocartis completed a €30 million (about $41.3 million) Series B equity financing round in April. Participants included the firm’s existing shareholders along with new investors Debiopharm Group and Johnson & Johnson Development Corporation, which each obtained a minority stake in Biocartis.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »